Related Experiment Video

Updated: May 25, 2026

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

Genomic complexity and AKT dependence in serous ovarian cancer

Aphrothiti J Hanrahan1, Nikolaus Schultz, Maggie L Westfal

  • 1Human Oncology and Pathogenesis Program, Memorial Sloan-Kettering Cancer Center, New York, NY 10471, USA.

Cancer Discovery
|February 14, 2012
PubMed
Abstract

Insights

Targeted therapies for ovarian cancer are lacking. This study found that while some ovarian cancers respond to AKT pathway inhibitors, genetic differences mean personalized molecular analysis is crucial for effective treatment.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • Effective oncoprotein-targeted therapies for ovarian cancer remain undeveloped.
  • The phosphatidylinositol 3-kinase (PI3K)/AKT signaling pathway is a key regulator of cell growth and survival, and its dysregulation is implicated in various cancers.

Purpose of the Study:

  • To investigate the role of PI3K/AKT signaling in ovarian cancer.
  • To determine the potential of AKT pathway inhibitors as targeted therapies for ovarian cancer.

Main Methods:

  • Genetic and functional analysis of ovarian cancer cell lines and patient tumors.
  • Assessment of PI3K pathway alterations and their correlation with sensitivity to AKT inhibition.
  • Evaluation of resistance mechanisms, including RAS pathway alterations and RB1 loss.

Main Results:

  • PI3K pathway alterations are frequent in ovarian cancer, with distinct mutational profiles.
  • Genetic activation of the PI3K pathway is necessary but not sufficient for sensitivity to AKT inhibition.
  • Ovarian cancer cells with RAS pathway alterations or RB1 loss exhibit resistance to AKT inhibition.
  • AKT1 inhibition induced growth arrest in a subset of cell lines, while AKT3 expression necessitated pan-AKT inhibition.

Conclusions:

  • A subset of ovarian cancers shows AKT pathway activation and sensitivity to selective AKT inhibitors.
  • Significant genetic heterogeneity in ovarian tumors necessitates an individualized treatment approach.
  • Successful application of PI3K/AKT pathway inhibitors requires real-time genomic and proteomic characterization of individual tumors.
Keywords:
AKTMK2206OvarianPTENTCGA

More Related Videos

Integration of Bioinformatics Approaches and Experimental Validations to Understand the Role of Notch Signaling in Ovarian Cancer09:08

Integration of Bioinformatics Approaches and Experimental Validations to Understand the Role of Notch Signaling in Ovarian Cancer

Published on: January 12, 2020

Heterogeneity Mapping of Protein Expression in Tumors using Quantitative Immunofluorescence07:54

Heterogeneity Mapping of Protein Expression in Tumors using Quantitative Immunofluorescence

Published on: October 25, 2011

Related Concept Videos

mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Adaptive Mechanisms in Cancer Cells02:53

Adaptive Mechanisms in Cancer Cells

Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Adaptive Mechanisms in Cancer Cells02:53

Adaptive Mechanisms in Cancer Cells

Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...
Cancers Originate from Somatic Mutations in a Single Cell02:21

Cancers Originate from Somatic Mutations in a Single Cell

Cancer arises from mutations in the critical genes that allow healthy cells to escape cell cycle regulation and acquire the ability to proliferate indefinitely. Though originating from a single mutation event in one of the originator cells, cancer progresses when the mutant cell lines continue to gain more and more mutations, and finally, become malignant. For example, chronic myelogenous leukemia (CML) develops initially as a non-lethal increase in white blood cells, which progressively...